Monogram Biosciences Gets Nasdaq Deficiency Letter | GenomeWeb
NEW YORK (GenomeWeb News) – Monogram Biosciences has received a staff deficiency letter from the Nasdaq Stock Market indicating that the firm failed to comply with a listing requirement regarding the market value of its stock.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.